Roser López-Alemany

Roser López-Alemany

UNVERIFIED PROFILE

Are you Roser López-Alemany?   Register this Author

Register author
Roser López-Alemany

Roser López-Alemany

Publications by authors named "Roser López-Alemany"

Are you Roser López-Alemany?   Register this Author

17Publications

337Reads

21Profile Views

Bcl-x inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas.

Sci Rep 2019 Mar 7;9(1):3816. Epub 2019 Mar 7.

Sarcoma Research Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-40106-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405759PMC
March 2019

Cell Death Identification in Anticancer Therapy-Response.

Cancer Res 2015 Sep 18;75(17):3682. Epub 2015 Aug 18.

Sarcoma Research Group, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-1540DOI Listing
September 2015

The importance of being dead: cell death mechanisms assessment in anti-sarcoma therapy.

Front Oncol 2015 7;5:82. Epub 2015 Apr 7.

Sarcoma Research Group, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat , Barcelona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fonc.2015.00082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387920PMC
April 2015

"(Not) all (dead) things share the same breath": identification of cell death mechanisms in anticancer therapy.

Cancer Res 2015 Mar 27;75(6):913-7. Epub 2015 Feb 27.

Sarcoma Research Group, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-14-3494DOI Listing
March 2015

Requirement of plasminogen binding to its cell-surface receptor α-enolase for efficient regeneration of normal and dystrophic skeletal muscle.

PLoS One 2012 11;7(12):e50477. Epub 2012 Dec 11.

IDIBELL-Institut d'Investigacions Biomèdiques de Bellvitge, Biological Clues of the Invasive and Metastatic Phenotype Research Group, L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0050477PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3519827PMC
May 2013

α-Enolase, a multifunctional protein: its role on pathophysiological situations.

J Biomed Biotechnol 2012 14;2012:156795. Epub 2012 Oct 14.

Biological Clues of the Invasive and Metastatic Phenotype Research Group, (IDIBELL) Institut d'Investigacions Biomèdiques de Bellvitge, L'Hospitalet de Llobregat, 08908 Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2012/156795DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479624PMC
April 2013

Alpha-enolase plasminogen receptor in myogenesis.

Front Biosci 2005 Jan 1;10:30-6. Epub 2005 Jan 1.

Institut de Recerca Oncologica, Centre d'Oncologia Molecular, L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2741/1503DOI Listing
January 2005

Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis.

Thromb Haemost 2003 Oct;90(4):724-33

Institut de Recerca Oncològia, Centre d'Oncología Molecular, L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1160/TH03-04-0291DOI Listing
October 2003

Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase.

Am J Hematol 2003 Apr;72(4):234-42

Centre d'Oncologia Molecular (C.O.M.), Institut de Recerca Oncolgica (IRO), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.10299DOI Listing
April 2003

Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding.

Eur J Biochem 2003 Mar;270(5):814-21

Institut de Recerca Oncològica (IRO), Centre d'Oncologia Molecular, L'Hospitalet de Llobregat, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1046/j.1432-1033.2003.03453.xDOI Listing
March 2003